The Molecular Quality Controls Market is experiencing a surge in demand as healthcare systems increasingly rely on molecular diagnostics for accurate and rapid disease detection. With the growing global burden of infectious diseases, genetic disorders, and cancer, the need for reliable testing mechanisms is at an all-time high. This rising demand for quality assurance and standardized protocols in clinical laboratories is fueling the adoption of molecular quality control products.
The global Molecular Quality Controls Market was valued at USD 163.69 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.8% during the forecast period. The market’s growth is driven by technological advancements in molecular testing, an increasing focus on laboratory accreditation, and stringent regulatory requirements for test accuracy.
Market Overview
Molecular quality controls are essential tools used in diagnostic laboratories to verify the accuracy, precision, and reliability of molecular assays. These controls are integrated into test workflows to detect potential errors, verify reagent performance, and ensure compliance with regulatory standards. Molecular quality controls are particularly critical in molecular diagnostics, which involve complex processes such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and real-time quantitative PCR.
These quality controls are commonly used in testing for infectious diseases (e.g., HIV, hepatitis, SARS-CoV-2), oncology (e.g., KRAS, BRAF mutations), and genetic disorders. They include internal quality controls (IQC), used within labs to monitor performance, and external quality assessment (EQA) materials, which evaluate a laboratory’s ability to perform specific tests against external benchmarks.
Key Market Growth Drivers
1. Surge in Molecular Diagnostic Testing
The global molecular diagnostics sector is witnessing exponential growth due to the rise in infectious and chronic diseases. Molecular testing has become the gold standard in COVID-19 detection, oncology profiling, and prenatal screening. This has led to an increased demand for molecular quality controls to maintain the accuracy and reproducibility of results. The widespread use of PCR and NGS technologies in clinical settings necessitates rigorous quality monitoring.
2. Regulatory Compliance and Accreditation
Accrediting bodies such as the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), and the International Organization for Standardization (ISO) have made it mandatory for laboratories to implement stringent quality assurance programs. Compliance with these standards requires the frequent use of molecular controls, further driving the market.
3. Technological Advancements
The development of multiplexed and synthetic controls has significantly enhanced laboratory workflows. Manufacturers are introducing customizable controls tailored for specific panels and instruments. Innovations like lyophilized and full-process controls improve stability and mimic clinical samples more closely, boosting market demand.
4. Expansion of Clinical Laboratory Networks
The increasing number of clinical laboratories globally, particularly in emerging economies, has created a favorable environment for molecular quality control products. These laboratories are expanding their testing menus, adopting advanced molecular assays, and seeking accreditation—all of which require dependable control systems.
Market Challenges
1. High Cost of Molecular Testing
Despite the growing demand, the high costs associated with molecular diagnostics and quality control materials remain a significant barrier, particularly in low- and middle-income countries. Smaller laboratories may struggle with the financial burden of frequent control testing, limiting widespread adoption.
2. Complex Regulatory Landscape
Navigating regulatory frameworks in different regions can be cumbersome for manufacturers. Compliance with diverse guidelines such as the EU’s In Vitro Diagnostic Regulation (IVDR) and the U.S. FDA’s Quality System Regulation (QSR) increases time to market and operational complexity.
3. Lack of Standardization Across Platforms
Different platforms and reagents require unique quality controls, creating a challenge for laboratories using multiple diagnostic systems. The lack of universal controls leads to increased inventory costs and operational burden.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/molecular-quality-controls-market
Regional Analysis
North America
North America dominates the Molecular Quality Controls Market, accounting for over 40% of global revenue in 2024. The presence of established molecular diagnostics players, stringent regulatory requirements, and well-funded healthcare infrastructure contribute to the region’s leadership. The U.S. remains a key market, driven by high test volumes, clinical laboratory networks, and ongoing investments in genomic medicine.
Europe
Europe holds the second-largest market share, supported by initiatives from the European Centre for Disease Prevention and Control (ECDC) and national public health agencies. The region’s emphasis on laboratory accreditation and external quality programs fosters growth. Countries like Germany, the U.K., and France are at the forefront, with robust diagnostics infrastructure.
Asia-Pacific
The Asia-Pacific region is expected to witness the fastest CAGR during the forecast period. Rising healthcare expenditure, improving laboratory capabilities, and increased adoption of molecular diagnostics in countries like China, India, Japan, and South Korea are driving market expansion. Government-backed initiatives for disease control and improved access to healthcare services are also contributing factors.
Latin America and the Middle East & Africa
These regions are gradually embracing molecular diagnostics, although growth is somewhat limited by cost and infrastructure challenges. However, international funding, training programs, and increasing awareness are fostering market opportunities. Brazil, South Africa, and Saudi Arabia are emerging markets in this domain.
Key Companies in the Market
The Molecular Quality Controls Market is moderately fragmented, with a mix of global and regional players. Companies are focusing on product innovation, strategic partnerships, and regional expansion to gain market share.
1. Bio-Rad Laboratories, Inc.
A leading provider of clinical diagnostics and life science research products, Bio-Rad offers an extensive range of molecular quality controls for infectious disease and genetic testing. Their AcroMetrix® product line is widely adopted in clinical labs.
2. Thermo Fisher Scientific Inc.
Thermo Fisher provides molecular controls through its Microbiome and Genetic Sciences division. The company leverages its strong distribution network and R&D capabilities to offer controls for NGS and PCR-based assays.
3. LGC SeraCare
LGC’s SeraCare division develops quality control materials for infectious disease and oncology testing. The company specializes in customizable and patient-like materials for assay development, validation, and quality monitoring.
4. Roche Diagnostics
Roche offers molecular control solutions as part of its integrated diagnostics portfolio. With a global footprint, Roche serves major healthcare systems and public health labs.
5. QuidelOrtho Corporation
QuidelOrtho produces quality control kits to support its portfolio of molecular testing products. Following its merger, the company is expanding its global reach and R&D capabilities.
Other notable players include:
- ZeptoMetrix Corporation
- Randox Laboratories Ltd
- Abbott Laboratories
- Seegene Inc.
- Grifols S.A.
Conclusion
The Molecular Quality Controls Market is poised for robust growth, driven by the increasing reliance on molecular diagnostics, stringent regulatory mandates, and ongoing technological innovation. As clinical laboratories seek to maintain quality assurance across a wide range of assays, the role of molecular quality controls becomes even more critical. With advancements in multiplex testing, synthetic control materials, and global disease surveillance programs, the market will continue to evolve and expand across regions.
For stakeholders—including diagnostics manufacturers, clinical laboratories, healthcare providers, and investors—the molecular quality controls market presents significant opportunities to enhance diagnostic accuracy, ensure patient safety, and comply with ever-tightening quality regulations.
More Trending Latest Reports By Polaris Market Research:
Testing, Inspection, and Certification Market
Europe Orthopedic Devices Market
3D Microfluidic Cell Culture Market
Organic Food And Beverages Market